You [hopefully] won't have to become a rare missed diagnosis because you didn't fit the demographic for this or that screening test.
Cost of genomic analysis is exponentially decreasing, and so much progress is happening so quickly.
Consider for example how in cardiology we advanced from ASCVD's 10-yr prognosis, to the PREVENT 30-yr prognosis. And still most providers are using the ASCVD score for their patients.
The chance a positive is real is so low you may as well just point to a body part and get it biopsied.
A positive from this kind of test is statistically meaningless.
If you let it give out tons of false positives, then patients are trained to ignore it when it cries wolf.
If you dial it back so that it gives out fewer positives, then now it starts giving out false negatives and not helping sick people.
Sadly, there's no perfect threshold when the signal and noise distributions overlap substantially, just different trade-offs.
(Love CI, btw!)
For example, single nucleotide polymorphisms. This way doctors spend less time guessing which medication is likely to work best for you when there are many options available.